SV Health Investors, LLC

Q2 2021 13F Holdings Report, Stock Holdings

Signature - Title
Brent M. Faduski - Officer
Location
Boston, MA
Holdings as of
30 Jun 2021
Value $
$229,564,000
Num holdings
7
Filing time
16 Aug 2021, 16:26:59 UTC
Form type
13F-HR
Description
All US holdings of this investor are reported in this report. Top holdings included AHCO, BCYC, MSON, STRO, and DCPH.
Previous filing
Q1 2021 - 17 May 2021
Next filing
Q3 2021 - 15 Nov 2021
Sym Weight Trade Impact Company Class Share Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2021 Q2 compared to 2021 Q1 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Brent M. Faduski Officer Boston, Massachusetts 16 Aug 2021

The filing of this report shall not be deemed an admission, for purposes of Section 13(t), 13(d), 13(g), or 16(a) under the Securities Exchange Act of 1934, as amended, and the rules thereunder, or for any other purpose, that the Reporting Manager or any other person (including Other Managers or Other Included Managers named herein) is the beneficial owner of any securities. SV Health Investors, LLC, a Delaware limited liability company ("Investors"), is an institutional investment manager subject to Section 13(f) of the Securities Exchange Act of 1934 and the rules promulgated thereunder. SV Life Sciences Fund IV, L.P. ("SVLS IV LP") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Strategic Partners IV" and together with SVLS IV LP, the "Fund IV Entities"), and SV Life Sciences Fund V, L.P. ("SVLS V LP") and SV Life Sciences Fund V Strategic Partners, L.P. ("Strategic Partners V" and together with SVLS V LP, the "Fund V Entities"), and SV Life Sciences Fund VI, L.P. ("SVLS VI LP") and SV Life Sciences Fund VI Strategic Partners, L.P. ("Strategic Partners VI" and together with SVLS VI LP, the "Fund VI Entities"), which are each Delaware limited partnerships (the Fund IV Entities, the Fund V Entities and the Fund VI Entities together, the "Funds"), directly own certain security positions reported by Investors, which is the investment adviser of the Funds. SV Life Sciences Fund VI (GP), L.P., a Delaware limited partnership ("SVLS VI GP") is the general partner of the Fund VI Entities, and SVLSF VI, LLC, a Delaware limited liability company is the general partner of SVLS VI GP. Certain of the security positions reported by Investors are also being reported by SVLS VI GP and SVLSF VI, LLC (together, the "GPs"). Each of SVLS VI GP, SVLSF VI, LLC and Investors may be deemed to share voting power and control over the shares held by the Fund VI Entities. Investors may also be deemed to share voting power and control over the shares held by the Fund IV and Fund V Entities. Each of the GPs and Investors disclaim beneficial ownership of the shares held by the Funds except to the extent of any pecuniary interest therein.

Other Included Managers (2):

Num Name Location File Number
1 SVLSF VI, LLC Boston, MA 028-19256
2 SV Life Sciences Fund VI (GP), L.P. Boston, MA 028-19255